ZLAB — Zai Lab Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1704292 ·
China
Last close
$23.53
Market Cap
$2.91B
52W High
$29.02
52W Low
$15.96
ADV30
1,127,960
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 108,208,000 | 56,903,000 | -62,978,000 | -46,136,000 | 1,023,896,000 | 549,658,000 | 460,617,000 |
| Jun 2026 | 106,311,000 | 58,149,000 | -76,489,000 | -50,825,000 | 1,074,793,000 | 607,522,000 | 467,756,000 |
| Mar 2026 | 99,611,000 | 61,276,000 | -69,279,000 | -51,016,000 | 1,095,737,000 | 651,316,000 | 433,756,000 |
| Dec 2025 | 127,597,000 | 65,266,000 | -68,264,000 | -50,409,000 | 1,172,384,000 | 679,573,000 | 456,884,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-159,208,000
Investing CF
$-47,682,000
Financing CF
$37,900,000
CapEx
$-37,954,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.90
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,776,597,000
Inventory
$85,292,000
Receivables
$75,397,000
ST Investments
$10,000,000
EBIT TTM
$-196,605,000
Pretax Income TTM
$-202,767,000
Interest Exp TTM
$6,162,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$449,614,016
EBITDA
$-248,168,000
Free Cash Flow
$-83,963,752
Enterprise Value
$2,196,723,968
Total Cash
$617,521,984
Total Debt
$254,576,000
Shares Out
123,772,253
Trailing EPS
$-1.80
Book Value
$6.47
ROE
-26.9%
ROA
-14.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 460,156,000 | -223,572,000 | -175,537,000 | 1,172,384,000 | 456,884,000 | 715,500,000 | -150,789,000 |
| Dec 2024 | 398,988,000 | -273,947,000 | -257,103,000 | 1,185,753,000 | 344,855,000 | 840,898,000 | -214,869,000 |
| Dec 2023 | 266,719,000 | -374,140,000 | -334,620,000 | 1,036,295,000 | 240,177,000 | 796,118,000 | -198,178,000 |
| Dec 2022 | 215,040,000 | -392,886,000 | -443,286,000 | 1,220,140,000 | 174,545,000 | 1,045,595,000 | -367,642,000 |
TTM Snapshot
Revenues TTM
$449,614,000
NetIncome TTM
$-188,213,000
OpCashFlow TTM
—
Assets (Latest)
$1,074,793,000
Forward EPS
$-2.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | $3.00B | $16.02 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.01B | $8.85 | — |
| XERS | Xeris Biopharma Holdings, Inc. | $3.07B | $16.80 | — |
| BGM | BGM Group Ltd. | $3.09B | $8.13 | — |
| LEGN | Legend Biotech Corp | $3.13B | $16.11 | — |
News headlines (Yahoo Finance, 1h cache)
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
2026-11-14 05:38 · Yahoo
Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
2026-11-14 03:26 · Yahoo
Zai Lab Announces Participation in Investor Conferences in November 2026
2026-11-13 21:35 · Yahoo
Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing
2026-11-13 18:02 · Yahoo
Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Li
2026-11-13 12:00 · Yahoo
Wall Street Analysts See a 40.17% Upside in Zai Lab Limited (ZLAB): Can the Stock Really Move This High?
2026-11-10 13:55 · Yahoo
Why Zai Lab Stock Is Up 12.7% And What's Next
2026-11-07 22:13 · Yahoo
Zai Lab (ZLAB) Draws Fresh Optimism, Is The Stock Still 24% Undervalued?
2026-11-07 08:15 · Yahoo
Zai Lab Ltd (ZLAB) Q3 2026 Earnings Call Highlights: Stabilizing China Business, Breakthrough ...
2026-11-07 05:07 · Yahoo
Zai Lab Q3 Earnings Call Highlights
2026-11-07 00:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.